Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Journal of Negative Results in BioMedicine

Volumn 13, Issue 1, 2014, Pages

  Maioli, Tatiani Uceli ^a   De Melo Silva, Brenda ^a   Dias, Michelle Nobre ^a   Paiva, Nivea Carolina ^b   Cardoso, Valbert Nascimento ^a   Fernandes, Simone Odilia ^a   Carneiro, Cláudia Martins ^b   Dos Santos Martins, Flaviano ^a   De Vasconcelos Generoso, Simone ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

5 fluorouracil; Intestinal permeability; Mucositis; Probiotic; Saccharomyces boulardii

Indexed keywords

PROBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENTERITIS; EXPERIMENTAL MUCOSITIS; FOOD INTAKE; IMMUNOGLOBULIN PRODUCTION; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; SACCHAROMYCES BOULARDII; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FEEDING BEHAVIOR; FLUOROURACIL; INTESTINAL MUCOSA; MICE; MUCOSITIS; PROBIOTICS; SACCHAROMYCES; WEIGHT LOSS;

EID: 84899985789     PISSN: None     EISSN: 14775751     Source Type: Journal    
DOI: 10.1186/1477-5751-13-6     Document Type: Article

References (42)

1. Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage. Prisciandaro LD, Geier MS, Chua AE, Butler RN, Cummins AG, Sander GR, Howarth GS, Support Care Cancer 2012 20 3205 3210 10.1007/s00520-012-1446-3 22526145
2. Cancer treatment-induced mucositis pain: strategies for assessment and management. Harris DJ, Ther Clin Risk Manag 2006 2 251 258 10.2147/tcrm.2006.2. 3.251 18360600
3. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Harris SM, Mistry P, Freathy C, Brown JL, Charlton PA, Br J Cancer 2005 92 722 728 10.1038/sj.bjc.6602403 15700035
4. Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters. Lopes NN, Plapler H, Lalla RV, Chavantes MC, Yoshimura EM, da Silva MA, Alves MT, Lasers Surg Med 2010 42 546 552 10.1002/lsm.20920 20662031
5. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Gibson RJ, Keefe DM, Support Care Cancer 2006 14 890 900 10.1007/s00520-006-0040-y 16604351
6. The combination of oral and small intestinal mucositis, pediatrics and biomarkers: a particularly tricky problem! Keefe DM, Gibson RJ, Cancer Biol Ther 2006 5 1282 1284 10.4161/cbt.5.10.3508 17172807
7. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Barasch A, Peterson DE, Oral Oncol 2003 39 91 100 10.1016/S1368-8375(02)00033-7 12509961
8. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Scully C, Epstein J, Sonis S, Head Neck 2004 26 77 84 10.1002/hed.10326 14724910
9. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D, Kelsen DP, Cancer 1999 86 1129 1134 10.1002/(SICI)1097-0142(19991001)86:7<1129::AID-CNCR5>3. 0.CO;2-4 10506695
10. Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Soares PM, Mota JM, Gomes AS, Oliveira RB, Assreuy AM, Brito GA, Santos AA, Ribeiro RA, Souza MH, Cancer Chemother Pharmacol 2008 63 91 98 10.1007/s00280-008-0715-9 18324404
11. Gut microbiome and intestinal mucositis: a new challenge for researchers. Gibson RJ, Cancer Biol Ther 2009 8 512 513 10.4161/cbt.8.6.7852 19411862
12. Infection Prevention in the Cancer Center. Thom KA, Kleinberg M, Roghmann MC, Clin Infect Dis 2013 4 579 585
13. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, Keefe DM, Exp Biol Med (Maywood) 2009 234 430 441 10.3181/0810-RM-301 19176868
14. Saccharomyces cerevisiae strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. Generoso SV, Viana M, Santos R, Martins FS, Machado JA, Arantes RM, Nicoli JR, Correia MI, Cardoso VN, Arch Microbiol 2010 192 477 484 10.1007/s00203-010-0574-8 20437166
15. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Generoso SV, Viana ML, Santos RG, Arantes RM, Martins FS, Nicoli JR, Machado JA, Correia MI, Cardoso VN, Eur J Nutr 2011 50 261 269 10.1007/s00394-010-0134-7 20936479
16. Guidelines For The Evaluation Of Probiotics In Food, Food And Agriculture Organization Of The United Nations & World Health Organization Working Group Report. FAO FaAOotUNaW, World Health Organization, Book Guidelines For The Evaluation Of Probiotics In Food, Food And Agriculture Organization Of The United Nations & World Health Organization Working Group Report (Editor Ed.^Eds.) City: FAO/WHO 2002
17. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. McFarland LV, Am J Gastroenterol 2006 101 812 822 10.1111/j.1572-0241.2006.00465.x 16635227
18. Safety of probiotics: translocation and infection. Liong MT, Nutr Rev 2008 66 192 202 10.1111/j.1753-4887.2008.00024.x 18366533
19. Biotherapeutic agents in the treatment of infectious diarrhea. Elmer GW, McFarland LV, Gastroenterol Clin North Am 2001 30 837 854 10.1016/S0889-8553(05) 70213-2 11586560
20. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ, BMJ 2002 324 1361 10.1136/bmj.324.7350.1361 12052801
21. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Czerucka D, Rampal P, Microbes Infect 2002 4 733 739 10.1016/S1286-4579(02) 01592-7 12067833
22. Effects of Saccharomyces boulardii on intestinal mucosa. Buts JP, De Keyser N, Dig Dis Sci 2006 51 1485 1492 10.1007/s10620-005-9016-x 16838119
23. Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Prisciandaro LD, Geier MS, Butler RN, Cummins AG, Howarth GS, Cancer Biol Ther 2011 11 671 677 10.4161/cbt.11.7.14896 21307648
24. Oral ingestion of Streptococcus thermophilus does not affect mucositis severity or tumor progression in the tumor-bearing rat. Tooley KL, Howarth GS, Lymn KA, Lawrence A, Butler RN, Cancer Biol Ther 2011 12 131 138 10.4161/cbt.12.2.15720 21508671
25. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Whitford EJ, Cummins AG, Butler RN, Prisciandaro LD, Fauser JK, Yazbeck R, Lawrence A, Cheah KY, Wright TH, Lymn KA, Howarth GS, Cancer Biol Ther 2009 8 505 511 10.4161/cbt.8.6.7594
26. Biochemical and Molecular Studies of Human Methenyltetrahydrofolate Synthetase. Jolivet J, Dayan A, Beauchemin M, Chahla D, Mamo A, Bertrand R, Oncologist 1996 1 248 254 10387998
27. 5-fluorouracil: mechanisms of action and clinical strategies. Longley DB, Harkin DP, Johnston PG, Nat Rev Cancer 2003 3 330 338 10.1038/nrc1074 12724731
28. The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Longley DB, Latif T, Boyer J, Allen WL, Maxwell PJ, Johnston PG, Semin Oncol 2003 30 3 9
29. Oral complications of cancer therapy. Sonis ST, Fey EG, Oncology (Williston Park) 2002 16 680 686 discussion 686, 691-682, 695 12108892
30. Role of endogenous microbiota, probiotics and their biological products in human health. Howarth GS, Wang H, Nutrients 2013 5 58 81 10.3390/nu5010058 23306189
31. Molecular mechanisms of platelet and stem cell rebound after 5-fluorouracil treatment. Li X, Slayton WB, Exp Hematol 2013 7 635 645,e3
32. Glutamine supplementation decreases intestinal permeability and preserves gut mucosa integrity in an experimental mouse model. dos Santos R, Viana ML, Generoso SV, Arantes RE, Davisson Correia MI, Cardoso VN, JPEN J Parenter Enteral Nutr 2010 34 408 413 10.1177/0148607110362530 20631386
33. Dual sugar gut-permeability testing on blood drop in animal models. Katouzian F, Sblattero D, Not T, Tommasini A, Giusto E, Meiacco D, Stebel M, Marzari R, Fasano A, Ventura A, Clin Chim Acta 2005 352 191 197 10.1016/j.cccn.2004.09.023 15653114
34. Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology. Sun Z, Wang X, Andersson R, Dig Surg 1998 15 386 397 10.1159/000018651 9845620
35. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Mauger CA, Butler RN, Geier MS, Tooley KL, Howarth GS, Dig Dis Sci 2007 52 612 619 10.1007/s10620-006-9464-y 17237997
36. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP, Infect Immun 2001 69 2762 2765 10.1128/IAI.69.4.2762-2765.2001 11254650
37. Role of hematopoietic microenvironment in prolonged impairment of B cell regeneration in age-related stromal-cell-impaired SAMP1 mouse: effects of a single dose of 5-fluorouracil. Tsuboi I, Hirabayashi Y, Harada T, Koshinaga M, Kawamata T, Kanno J, Inoue T, Aizawa S, J Appl Toxicol 2008 28 797 805 10.1002/jat.1341 18344199
38. Effects of 5-fluorouracil on B lymphocyte lineage cells. Vetvicka V, Kincade PW, Witte PL, J Immunol 1986 137 2405 2410 3093575
39. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC, Am J Physiol Gastrointest Liver Physiol 2011 301 1083 1092 10.1152/ajpgi.00217.2011 21903765
40. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Martins FS, Vieira AT, Elian SD, Arantes RM, Tiago FC, Sousa LP, Araujo HR, Pimenta PF, Bonjardim CA, Nicoli JR, Teixeira MM, Microbes Infect 2013 15 270 279 10.1016/j.micinf.2012.12.007 23376166
41. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC, Clin Exp Immunol 2009 156 78 87 10.1111/j.1365-2249.2009.03878.x 19161443
42. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Sezer A, Usta U, Cicin I, Med Oncol 2009 26 350 357 10.1007/s12032-008-9128-1 19067257